Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Schering-Plough Announces Two European Filings

By Pharmaceutical Processing | August 26, 2009

Schering-PloughCorporation has announced that the European Medicines Agency(EMEA) has validated (accepted for review) the company’s MarketingAuthorization Application (MAA) for a fixed-dose combination of mometasonefuroate and formoterol fumarate for the maintenance treatment of asthma inpatients 12 years of age and older. The company also announced today that theEMEA has validated the MAA for nomegestrol acetate (2.5 mg) / 17beta-estradiol (1.5mg), a combined oral contraceptive (COC) containing aunique combination of a natural estrogen identical to the estrogen produced bya woman’s own body and a selective progestin. Mometasone furoate/formoterol fumarate combines mometasone furoate, theactive ingredient of the inhaled corticosteroid, ASMANEX , with formoterolfumarate, the active ingredient of the long-acting beta2-agonist, FORADIL ,administered via a single metered-dose inhaler. Marketing approval from the EMEA is being sought for nomegestrolacetate/17 beta-estradiol as an oral treatment for women to prevent pregnancy.Both applications will follow the Centralized Procedure. “These two regulatory milestones are important steps toward advancing ourlate-stage pipeline and meeting patient needs. If approved by the EMEA, themometasone furoate/formoterol fumarate combination would represent animportant additional treatment option for physicians and their patients andfurther strengthen Schering-Plough’s portfolio of respiratory products,” saidThomas P. Koestler, Ph.D., executive vice president and president,Schering-Plough Research Institute. “Schering-Plough is also committed toproviding women a variety of birth control options to meet diverse lifestyleneeds and choices.”

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE